The European Medicines Agency (EMA) on April 8, 2026, launched a campaign aimed at increasing awareness and proper use of package leaflets for veterinary medicines across the European Union. The initiative targets veterinarians, animal owners, and other stakeholders involved in animal healthcare, seeking to improve understanding of dosage, administration, and safety information contained in the leaflets.
Document Context and Type
The campaign was announced by EMA's Veterinary Medicines Division as a non-binding awareness initiative, not a regulatory change. It follows the agency's recent data protection notice for the Pre-Accession Assistance Programme (IPA) issued on April 7, 2026, and the Pharmacovigilance Risk Assessment Committee's (PRAC) new drug safety monitoring recommendations adopted on the same day. The campaign complements these efforts by focusing on the end-user's comprehension of veterinary medicine information.
Policy Orientations and Trade-offs
enhancing user education to reduce medication errors and promoting responsible use of veterinary medicines. By encouraging stakeholders to read and follow package leaflets, the EMA aims to improve treatment outcomes and minimize adverse events. However, the campaign may impose a moderate administrative burden on veterinary practices and animal owners who must allocate time to review materials, potentially slowing down treatment processes.
Impact on Stakeholders - Veterinarians and veterinary clinics: May benefit from reduced medication errors and clearer communication with clients, but face additional time spent explaining leaflet contents. - Animal owners and livestock producers: Gain better understanding of proper medicine use, leading to improved animal health, but may experience increased complexity in administering treatments. - Pharmaceutical companies producing veterinary medicines: Could see reduced liability from misuse, but may need to update leaflets to align with campaign messages, incurring minor costs. - National competent authorities: May use campaign materials to support their own outreach, but have no new compliance obligations.
Expected Institutional Follow-up
The EMA plans to monitor the campaign's reach through surveys and feedback from stakeholders. No new regulatory measures are anticipated, but the campaign may inform future revisions of veterinary medicine information requirements under EU pharmaceutical legislation.
← Atlas › News › Agri-food